Chemoreflex Sensitivity in Chronic Kidney Disease

This study has been completed.
Sponsor:
Collaborators:
Heinrich-Heine University, Duesseldorf
Medical Clinic I, SLK-Kliniken Heilbronn
Information provided by:
RWTH Aachen University
ClinicalTrials.gov Identifier:
NCT00794872
First received: November 19, 2008
Last updated: NA
Last verified: November 2008
History: No changes posted
  Purpose

Cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (CKD) and may be explained in part by sympathetic hyperactivity. Impaired hyperoxic chemoreflex sensitivity (CHRS) has been attributed to an increased sympathetic activity. The aim of the present study is to examine whether chemosensor function is altered in patients with stage 3 and stage 4 CKD.


Condition Intervention
Chronic Kidney Disease
Cardiovascular Morbidity
Other: blood sampling

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by RWTH Aachen University:

Primary Outcome Measures:
  • Hyperoxic chemoreflex sensitivity is impaired in patients with moderate to severe chronic kidney disease [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Measurement of the venous partial pressure of oxygen in blood samples


Enrollment: 65
Study Start Date: January 2007
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Patients with stage 3 CKD
Other: blood sampling
2
Patients with stage 4 CKD
Other: blood sampling
3
Patients without evidence for CDK
Other: blood sampling

Detailed Description:

Impaired hyperoxic chemoreflex sensitivity (CHRS) is assessed in patients with stage 3 CKD [glomerular filtration rate (GFR) 30-59 ml/min/1.73 m2], in patients with stage 4 CKD [GFR 15-29 ml/min/1.73 m2], as well as in patients without any evidence of CKD. CHRS is measured by determination of the venous partial pressure of oxygen and the heart rate before and after deactivation of the chemoreceptors by inhalation of pure oxygen. The difference in the R-R intervals before and after inhalation divided by the difference in the oxygen pressures is calculated as the CHRS. A CHRS below 3.0 ms/mmHg is defined as pathological. It should be shown that using a simple clinical bedside test we provide the first evidence for impaired hyperoxic chemoreflex sensitivity in stage 3 and 4 chronic kidney disease. We thereby may lay the basis for future intervention studies assessing chemosensor function in these patients.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29 ml/min/1.73 m²)
  • For the reference Patients without evidence for CDK

Exclusion Criteria:

  • Patients with heart failure, history of myocardial infarction or instable angina pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep apnoea syndrome, alcohol abuse and drug induced cardiomyopathy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00794872

Locations
Germany
Department of Medicine, Division of Cardiology, Pulmonology and Vascular Medicine
Aachen, NRW, Germany, 52074
Sponsors and Collaborators
RWTH Aachen University
Heinrich-Heine University, Duesseldorf
Medical Clinic I, SLK-Kliniken Heilbronn
Investigators
Principal Investigator: Christian Meyer, MD RWTH Aachen University Departement of Cardiology, Pulmonology and Vascular Medicine
  More Information

No publications provided

Responsible Party: Christian Meyer, MD, RWTH Aachen University
ClinicalTrials.gov Identifier: NCT00794872     History of Changes
Other Study ID Numbers: Chemoreflex-Sensitivity-Study
Study First Received: November 19, 2008
Last Updated: November 19, 2008
Health Authority: Germany: Ethics Committee

Keywords provided by RWTH Aachen University:
Cardiovascular autonomic neuropathy
Chemoreflex sensitivity
Chronic kidney disease
Sudden cardiac arrest

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency

ClinicalTrials.gov processed this record on April 17, 2014